The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma. Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.